07/25/2020, 12.48
Send to a friend

COVID-19 clinical trials begin

Biopharma giant Celltrion announces clinical trials following government approval.  Antibodies will be used to fight the coronavirus outbreak, which hit China and Korea hard.


Seoul (AsiaNews) – South Korean biopharma giant Celltrion announced clinical trials for a potential vaccine against COVID-19, after South Korea’s Ministry of Food and Drug Safety gave the green light.

The first stage began yesterday in collaboration with Chungnam University. The treatment is based on the antibodies developed by the human body during the infection. The hope is to understand how to reproduce them in the laboratory.

The first quarter of 2021 will see the application of the protocol to coronavirus patients still infected. According to some scientists, this could help understand how to speed up the development of antibodies.

South Korea, along with China, was initially hit hard by the COVID-19 outbreak. The South Korean government has repeatedly stated that it wants to do everything possible to eradicate the viral threat as soon as possible.

Send to a friend
Printable version
See also
Tensions between Seoul and Pyongyang rise as Cold War fears cast a shadow over Korea
12/02/2016 15:14
With Beijing’s help, Jakarta plans to produce 50 million doses of anti-COVID vaccine
24/08/2020 12:23
Coronavirus epidemic slows in Korea for the third consecutive day
09/03/2020 09:24
Avian flu: Hanoi announces new drug trials
Korean bishops urge prayers for national unity and Christian rebirth


Subscribe to Asia News updates or change your preferences

Subscribe now
“L’Asia: ecco il nostro comune compito per il terzo millennio!” - Giovanni Paolo II, da “Alzatevi, andiamo”